AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Pyruvate kinase (PK) deficiency is a rare genetic disease that causes chronic hemolytic anemia. There are currently no targeted therapies for PK deficiency. Here, we describe the identification and characterization of AG-348, an allosteric activator of PK that is currently in clinical trials for the treatment of PK deficiency. We demonstrate that AG-348 can increase the activity of wild-type and mutant PK enzymes in biochemical assays and in patient red blood cells treated ex vivo. These data illustrate the potential for AG-348 to restore the glycolytic pathway activity in patients with PK deficiency and ultimately lead to clinical benefit.

[1]  M. Salek,et al.  Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency , 2018, Quality of Life Research.

[2]  D. Morton,et al.  Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study , 2016 .

[3]  A. Schambach,et al.  Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Maria De Bonis,et al.  Red blood cell PK deficiency: An update of PK-LR gene mutation database. , 2016, Blood cells, molecules & diseases.

[5]  P. Newburger,et al.  Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants , 2015 .

[6]  F. Prósper,et al.  Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells , 2015, Stem cell reports.

[7]  D. Morton,et al.  Erythrocyte pyruvate kinase deficiency: 2015 status report , 2015, American journal of hematology.

[8]  William J. Israelsen,et al.  Pyruvate kinase: Function, regulation and role in cancer. , 2015, Seminars in cell & developmental biology.

[9]  William J. Israelsen,et al.  ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model , 2013 .

[10]  L. Cantley,et al.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. , 2012, Chemistry & biology.

[11]  M. Weiss,et al.  Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia. , 2012, Blood.

[12]  Nir S. Gov,et al.  Metabolic remodeling of the human red blood cell membrane , 2010, Proceedings of the National Academy of Sciences.

[13]  J. Segovia,et al.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  K. Kain,et al.  Adenosine triphosphate depletion of erythrocytes simulates the phenotype associated with pyruvate kinase deficiency and confers protection against Plasmodium falciparum in vitro. , 2009, The Journal of infectious diseases.

[15]  Richard van Wijk,et al.  The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis , 2005 .

[16]  Paola Bianchi,et al.  Red cell pyruvate kinase deficiency: molecular and clinical aspects , 2005, British Journal of Haematology.

[17]  Laurent Kiger,et al.  Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells , 2005, Nature Biotechnology.

[18]  Yutaka Kawakami,et al.  Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency , 2003, American journal of hematology.

[19]  A. Galizzi,et al.  Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. , 2001, Blood.

[20]  A. Zanella,et al.  Red cell pyruvate kinase deficiency: from genetics to clinical manifestations. , 2000, Bailliere's best practice & research. Clinical haematology.

[21]  B. Stoddard,et al.  The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. , 1998, Structure.

[22]  A. Zanella,et al.  Molecular characterization of PK-LR gene in pyruvate kinase-deficient Italian patients. , 1997, Blood.

[23]  I. A. Hansen,et al.  pH, Temperature and Lactate Production in Human Red Blood Cells: Implications for Blood Storage and Glycolytic Control , 1992, Vox sanguinis.

[24]  G. Bartosz,et al.  Aging of the erythrocyte. XIV. ATP content does decrease , 1982, Experientia.

[25]  G. Bartosz,et al.  Aging of the erythrocyte , 1980, Blut.

[26]  E. Orringer,et al.  Quinine protects pyruvate‐kinase deficient red cells from dehydration , 1979, American journal of hematology.

[27]  R. Zahler.  Enzyme Structure and Mechanism , 1979, The Yale Journal of Biology and Medicine.

[28]  G. Löhr,et al.  Effect of riboflavin treatment on human red cell pyruvate kinase deficiency. , 1976, Clinica chimica acta; international journal of clinical chemistry.

[29]  B. Glader.  Salicylate-induced injury of pyruvate-kinase-deficient erythrocytes. , 1976, The New England journal of medicine.

[30]  T. V. van Berkel,et al.  Normalisation of red blood cell pyruvate kinase in pyruvate kinase deficiency by riboflavin treatment. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[31]  D. Nathan,et al.  Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. , 1971, The Journal of clinical investigation.

[32]  F. Oski,et al.  A Low Km Phosphoenolpyruvate Mutant in the Amish with Red Cell Pyruvate Kinase Deficiency , 1969, British journal of haematology.

[33]  E. Merrill,et al.  Metabolic dependence of red cell deformability. , 1969, The Journal of clinical investigation.

[34]  F. Oski,et al.  Life-span and organ sequestration of the red cells in pyruvate kinase deficiency. , 1968, The New England journal of medicine.

[35]  F. Oski,et al.  ERYTHROCYTE PYRUVATE KINASE DEFICIENCY RESULTING IN CONGENITAL NONSPHEROCYTIC HEMOLYTIC ANEMIA. , 1963, The New England journal of medicine.

[36]  P. Brunetti,et al.  Haemolytic anaemia due to pyruvate-kinase deficiency. , 1963, Lancet.

[37]  W. Valentine,et al.  Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. , 1962, Blood.

[38]  Wouter W van Solinge,et al.  The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. , 2005, Blood.

[39]  P. Huppke,et al.  Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes. , 1994, Enzyme & protein.

[40]  Ernest Beutler,et al.  Red Cell Metabolism: A Manual of Biochemical Methods , 1975 .

[41]  D. Germain.  [Apropos of 3 new types of hemolytic anemia in children. Infantile pyknocytosis. Familial hemolytic anemia with erythrocytic inclusions and pigmenturia. Anemia caused by pyruvate-kinase deficiency]. , 1962, Pediatrie.